A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination With Either Venetoclax or Placebo in Subjects With Relapsed or Refractory Multiple Myeloma Who Are Sensitive or Naïve to Proteasome Inhibitors
Phase of Trial: Phase III
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Venetoclax (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 31 Aug 2017 Planned End Date changed from 15 Jun 2020 to 2 Sep 2019.
- 31 Aug 2017 Planned primary completion date changed from 27 Dec 2019 to 2 Sep 2019.
- 10 Jun 2017 Biomarkers information updated